AML with Recurrent Genetic Abnormalities

AML with Recurrent Genetic Abnormalities — Trials · CancerIndex

Clinical trials

Registered studies

183 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 10
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 20%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (35)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03147612	Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia	active not recruiting	Phase 2	22	M.D. Anderson Cancer CenterOTHER	1	Aug 19, 2026	clinicaltrials
NCT00658814	Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia	active not recruiting	Phase 2	133	National Cancer Institute (NCI)NIH	1	Jul 1, 2026